Comparison of anticancer drug coverage decisions in the United States and United Kingdom: does the evidence support the rhetoric?

Publication Type:

Journal Article


Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 28, Issue 20, p.3234-8 (2010)


2010, Antineoplastic Agents, Center-Authored Paper, Cost-Benefit Analysis, Decision Making, Drug Approval, Great Britain, Health Services Accessibility, Humans, Insurance, Health, Reimbursement, Medicare, National Health Programs, Public Health Sciences Division, Time Factors, United States, United States Food and Drug Administration


In contrast to the United States, several European countries have health technology assessment programs for drugs, many of which assess cost effectiveness. Coverage decisions that consider cost effectiveness may lead to restrictions in access.